Regenxbio INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

5 Mar 2026

RGNX

10-K: REGENXBIO Faces Regulatory Hurdles, Going Concern Doubt Despite Revenue Growth

REGENXBIO reported increased revenues and a reduced net loss in 2025, driven by new partnerships, but faces significant regulatory setbacks for its MPS I and MPS II gene therapies and a going concern warning.

NASDAQ

13 Mar 2025

RGNX

Regenxbio INC

10-K: REGENXBIO Inc. Reports 2024 Results, Highlights Pipeline Progress and Strategic Partnerships

REGENXBIO Inc.'s 2024 10-K filing details the company's financial performance, pipeline advancements, and strategic collaborations, including partnerships with AbbVie and Nippon Shinyaku.

NASDAQ

27 Feb 2024

RGNX

Regenxbio INC

10-K: REGENXBIO Inc. Files 10-K Report, Highlights Progress in Gene Therapy Pipeline

REGENXBIO Inc. released its 10-K filing, detailing its financial results for 2023 and providing updates on its clinical-stage gene therapy programs.